The US Food and Drug Administration (FDA) last month sent the University of California Los Angeles (UCLA) an untitled letter over promotional claims about an imaging test that uses an unapproved ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, ...

Study combines highly focused radiation with targeted radioactive therapy drug designed to seek out and destroy cancer cells with minimal damage to healthy tissue The Phase 2 trial, called ANDROMEDA, ...

UCLA researchers found that routine PSMA PET/CT scans could help doctors select treatment approaches for the best long-term outcomes in patients with recurring prostate cancer after surgical removal ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...